Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
TLDR
ACIP did not recommend catch-up vaccination for all adults aged 27 through 45 years, but recognized that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range.Abstract:
Vaccination against human papillomavirus (HPV) is recommended to prevent new HPV infections and HPV-associated diseases, including some cancers. The Advisory Committee on Immunization Practices (ACIP)* routinely recommends HPV vaccination at age 11 or 12 years; vaccination can be given starting at age 9 years. Catch-up vaccination has been recommended since 2006 for females through age 26 years, and since 2011 for males through age 21 years and certain special populations through age 26 years. This report updates ACIP catch-up HPV vaccination recommendations and guidance published in 2014, 2015, and 2016 (1-3). Routine recommendations for vaccination of adolescents have not changed. In June 2019, ACIP recommended catch-up HPV vaccination for all persons through age 26 years. ACIP did not recommend catch-up vaccination for all adults aged 27 through 45 years, but recognized that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range; therefore, ACIP recommended shared clinical decision-making regarding potential HPV vaccination for these persons.read more
Citations
More filters
Journal ArticleDOI
Head and neck squamous cell carcinoma
Daniel Johnson,Barbara Burtness,C. René Leemans,Vivian Wai Yan Lui,Julie E. Bauman,Jennifer R. Grandis +5 more
TL;DR: This Primer provides an overview of the epidemiology, pathogenesis and treatment of HNSCCs of different aetiologies and the effects of the cancer and its treatment on patient quality of life.
Journal ArticleDOI
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2018.
TL;DR: The Advisory Committee on Immunization Practices (ACIP) voted to recommend approval of the 2020 Recommended U.S. Adult Immunization Schedule for Persons Aged 19 Years and Older, which has been approved by the CDC Director, the American College of Physicians, and the American Academy of Family Physicians.
Journal ArticleDOI
Human Papillomavirus-Attributable Cancers - United States, 2012-2016.
Virginia Senkomago,S. Jane Henley,Cheryll C. Thomas,Jacqueline M. Mix,Lauri E. Markowitz,Mona Saraiya +5 more
TL;DR: These surveillance data from population-based cancer registries can be used to inform the planning for, and monitor the long-term impact of, HPV vaccination and cancer screening efforts nationally and within states.
Journal ArticleDOI
Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.
Peng-jun Lu,Mei-Chuan Hung,Anup Srivastav,Lisa A. Grohskopf,Miwako Kobayashi,Aaron M. Harris,Kathleen L. Dooling,Lauri E. Markowitz,Alfonso Rodriguez-Lainz,Walter W. Williams +9 more
TL;DR: In 2018, the National Health Interview Survey (NHIS) reported that the U.S. adult vaccination coverage among males aged 19-26 years increased 5.2 and 6.7 percentage points to 30.3% from the 2017 estimate as mentioned in this paper.
Journal ArticleDOI
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.
Torsten Kucharzik,Pierre Ellul,T Greuter,J F Rahier,Bram Verstockt,Candida Abreu,Andreia Albuquerque,Mariangela Allocca,Maria Esteve,Francis A Farraye,Hannah Gordon,Konstantinos Karmiris,Uri Kopylov,Julien Kirchgesner,Eithne MacMahon,Fernando Magro,Christian Maaser,L. de Ridder,Carlos Taxonera,M Toruner,Lydjie Tremblay,Michael Scharl,N. Viget,Yamile Zabana,Stephan R. Vavricka +24 more
References
More filters
Journal Article
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Emiko Petrosky,Joseph A. Bocchini,Susan Hariri,Harrell W. Chesson,C. Robinette Curtis,Mona Saraiya,Elizabeth R. Unger,Lauri E. Markowitz +7 more
TL;DR: Evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination is summarized and recommendations for vaccine use are provided.
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Lauri E. Markowitz,Eileen F. Dunne,Mona Saraiya,Harrell W. Chesson,Curtis Cr,Julianne Gee,Joseph A. Bocchini,Elizabeth R. Unger +7 more
TL;DR: This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines.
Journal ArticleDOI
Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.
TL;DR: Recommendations and guidance regarding use of HPV vaccines are provided and new recommendations for use of a 2-dose schedule for girls and boys who initiate the vaccination series at ages 9 through 14 years are included.
Journal ArticleDOI
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017
Tanja Y. Walker,Laurie D. Elam-Evans,David Yankey,Lauri E. Markowitz,Charnetta Williams,Sarah Mbaeyi,Benjamin Fredua,Shannon Stokley +7 more
TL;DR: Although HPV vaccination initiation remains lower than coverage with MenACWY and Tdap, HPV vaccination coverage has increased an average of 5.1 percentage points annually since 2013, indicating that continued efforts to target unvaccinated teens and eliminate missed vaccination opportunities might lead to HPV vaccination Coverage levels comparable to those of other routinely recommended adolescent vaccines.
Journal ArticleDOI
The estimated lifetime probability of acquiring human papillomavirus in the United States.
TL;DR: The results are consistent with estimates in the existing literature suggesting a high lifetime probability of HPV acquisition and are supported by cohort studies showing high cumulative HPV incidence over a relatively short period, such as 3 to 5 years.